Opportunity Information: Apply for W81XWH 15 BCRP BREAKTHROUGH2 FL3
Apply for W81XWH 15 BCRP BREAKTHROUGH2 FL3
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer Breakthrough Award Level 3 Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on Jul 23, 2015 and posted on Jul 23, 2015.
- Applicants must submit their applications by Dec 21, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $11,250,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The DoD Breast Cancer Breakthrough Award Level 3 (Funding Opportunity Number W81XWH 15 BCRP BREAKTHROUGH2 FL3) is a U.S. Army Medical Research Acquisition Activity (USAMRAA) funding opportunity intended to back breast cancer research that is genuinely positioned to change the field, not just add another incremental step. The program is built around the idea of "impact" and expects applicants to make a clear case that their work could meaningfully accelerate progress toward ending breast cancer. Importantly, the Department of Defense is not limiting impact to immediate patient-facing outcomes; instead, proposals must explain a believable pathway to clinical impact for people with breast cancer or those at risk, even if the project itself is not the final clinical deliverable.
Level 3 is specifically aimed at advanced translational research that is close enough to human application to support near-term clinical investigation. In practice, this means projects should be beyond early discovery and should be positioned to move a promising concept toward clinical testing, validation, or implementation. The announcement explicitly notes that small-scale clinical trials may apply, which signals that proposals can include early clinical studies when they are well-justified and appropriately designed for the stage of development. The broader Breakthrough Award mechanism can support projects ranging from small to large scale and across different levels of idea maturity, but this particular announcement covers only Funding Level 3; separate announcements were planned for Funding Levels 1 and 2.
A notable feature is the Partnering PI Option, which encourages meaningful collaboration between two principal investigators. Under this structure, there is an Initiating PI and a Partnering PI, and each PI receives a separate award while contributing jointly to a single, integrated research project. The program emphasizes that both investigators should play substantial roles in shaping the project narrative, statement of work, and other core components, and that each PI must bring distinct expertise rather than duplicating the same role. Collaborations can be new or existing, but the application needs to explain why doing the work together creates added value compared with running two separate projects. The program also discourages investigators from serving as a Partnering PI on multiple applications unless those applications clearly pursue different research questions, which is meant to keep collaborations focused and substantive.
The opportunity places strong expectations on team composition and engagement. The PI or PI team is expected to assemble a robust, appropriately skilled group with the breast cancer-relevant expertise needed to execute a translational project and, where applicable, clinical components such as recruitment, oversight, and evaluation. A required and central element is consumer advocate involvement: every application must include at least two breast cancer consumer advocates who are integrated throughout planning and implementation rather than added as a symbolic advisory layer. These advocates are expected to contribute to core aspects such as refining the research question, shaping the study design, providing oversight input, advising on recruitment approaches, and participating in evaluation. The announcement also sets clear eligibility and independence standards for advocates: they must be individuals diagnosed with breast cancer, active in a breast cancer advocacy organization, and not employees of any participating organization on the application. Their role is intended to provide independent, objective input focused on patient relevance and real-world impact, and they are expected to have sufficient knowledge of breast cancer issues and research to participate effectively.
From an administrative standpoint, this is a discretionary funding opportunity using a cooperative agreement or grant mechanism under the Science and Technology and other Research and Development category. The CFDA listing is 12.420 (Military Medical Research and Development). The agency anticipated making about three awards, with an estimated total funding amount of $11.25 million, and it did not require cost sharing or matching. Eligibility was broadly unrestricted (open to any entity type), subject to any specific clarifications in the full announcement. The opportunity was posted July 23, 2015, with an application closing date of December 21, 2015, and it was later archived on January 20, 2016. For access issues, applicants were directed to the CDMRP Help Desk at 301-682-5507.
FAQs: DoD Breast Cancer Breakthrough Award Level 3 (W81XWH 15 BCRP BREAKTHROUGH2 FL3)
What is this funding opportunity?
The DoD Breast Cancer Breakthrough Award Level 3 (Funding Opportunity Number W81XWH 15 BCRP BREAKTHROUGH2 FL3) is a U.S. Army Medical Research Acquisition Activity (USAMRAA) opportunity intended to support breast cancer research that is positioned to change the field, with a strong emphasis on measurable impact rather than incremental progress.
What is the program trying to achieve?
The program is built around the concept of "impact" and expects applicants to clearly explain how the proposed work could meaningfully accelerate progress toward ending breast cancer. The opportunity emphasizes a credible pathway to clinical impact for people with breast cancer or those at risk, even if the project itself is not the final clinical deliverable.
Does the project need to deliver an immediate patient-facing outcome?
No. The Department of Defense does not limit impact to immediate patient-facing outcomes. However, applications must describe a believable pathway to clinical impact for people with breast cancer or those at risk.
What kind of research does Level 3 support?
Level 3 is aimed at advanced translational research that is close enough to human application to support near-term clinical investigation. Projects should be beyond early discovery and positioned to move a promising concept toward clinical testing, validation, or implementation.
Are clinical trials allowed under this opportunity?
Yes. The announcement explicitly notes that small-scale clinical trials may apply, indicating that proposals can include early clinical studies when they are well-justified and appropriately designed for the stage of development.
Is this announcement for all Breakthrough Award funding levels?
No. This particular announcement covers only Funding Level 3. Separate announcements were planned for Funding Levels 1 and 2.
How many awards were expected to be made?
The agency anticipated making about three awards.
What was the estimated total funding amount?
The estimated total funding amount was $11.25 million.
Is cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
Who was eligible to apply?
Eligibility was described as broadly unrestricted (open to any entity type), subject to any specific clarifications in the full announcement.
What funding mechanism or award type is used?
This was a discretionary funding opportunity using a cooperative agreement or grant mechanism under the Science and Technology and other Research and Development category.
What is the CFDA number associated with this opportunity?
The CFDA listing is 12.420 (Military Medical Research and Development).
What is the Partnering PI Option?
The Partnering PI Option encourages meaningful collaboration between two principal investigators. Under this structure, there is an Initiating PI and a Partnering PI, and each PI receives a separate award while contributing jointly to a single, integrated research project.
Do both PIs need to contribute substantially under the Partnering PI Option?
Yes. The program emphasizes that both investigators should play substantial roles in shaping the project narrative, statement of work, and other core components.
Do the two PIs need to bring different expertise?
Yes. Each PI must bring distinct expertise rather than duplicating the same role.
Can the collaboration be new, or must it be established?
Collaborations can be new or existing, but the application needs to explain why doing the work together adds value compared with running two separate projects.
Can someone serve as a Partnering PI on multiple applications?
The program discourages investigators from serving as a Partnering PI on multiple applications unless those applications clearly pursue different research questions.
What expectations are there for the overall research team?
The PI or PI team is expected to assemble a robust, appropriately skilled group with breast cancer-relevant expertise needed to execute a translational project and, where applicable, clinical components such as recruitment, oversight, and evaluation.
Are consumer advocates required?
Yes. Every application must include at least two breast cancer consumer advocates.
How should consumer advocates be involved in the project?
They must be integrated throughout planning and implementation rather than added as a symbolic advisory layer. The opportunity describes their expected contributions to core aspects such as refining the research question, shaping the study design, providing oversight input, advising on recruitment approaches, and participating in evaluation.
Who qualifies as a breast cancer consumer advocate for this opportunity?
Consumer advocates must be individuals diagnosed with breast cancer, active in a breast cancer advocacy organization, and not employees of any participating organization on the application.
Why must consumer advocates be independent from participating organizations?
Their role is intended to provide independent, objective input focused on patient relevance and real-world impact.
Do consumer advocates need specific knowledge or experience?
Yes. The announcement indicates they are expected to have sufficient knowledge of breast cancer issues and research to participate effectively.
When was this opportunity posted, and when did it close?
The opportunity was posted on July 23, 2015, and the application closing date was December 21, 2015.
Is this opportunity still open?
No. It was later archived on January 20, 2016.
Who should applicants contact if they have trouble accessing the application?
For access issues, applicants were directed to the CDMRP Help Desk at 301-682-5507.
Which organization administered this funding opportunity?
The opportunity is associated with the U.S. Army Medical Research Acquisition Activity (USAMRAA) within the Department of Defense.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Supplements to Support Evaluation of the NCI Cancer Genomics Cloud Pilots (Admin Supp)
Previous opportunity: FY 2015 Marine Minerals Branch (MMB)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 15 BCRP BREAKTHROUGH2 FL3
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 15 BCRP BREAKTHROUGH2 FL3) also looked into and applied for these:
| Funding Opportunity |
|---|
| FY15 Supplemental for Evaluation of Wheel/Rail Contact Mechanics, VT Apply for FR RRD 15 015 Funding Number: FR RRD 15 015 Agency: DOT/Federal Railroad Administration Category: Science and Technology and other Research and Development Funding Amount: $231,000 |
| CISE Research Infrastructure Apply for 15 590 Funding Number: 15 590 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,500,000 |
| Biotechnology and Biochemical Engineering Apply for PD 15 1491 Funding Number: PD 15 1491 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Nano Biosensing Apply for PD 15 7909 Funding Number: PD 15 7909 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Nano Bio Phenomena and Processes in the Environment Apply for PD 15 1179 Funding Number: PD 15 1179 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Engineering Apply for PD 15 1440 Funding Number: PD 15 1440 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Fluid Dynamics Apply for PD 15 1443 Funding Number: PD 15 1443 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| General Age Related Disabilities Engineering Apply for PD 15 5342 Funding Number: PD 15 5342 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biomedical Engineering Apply for PD 15 5345 Funding Number: PD 15 5345 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Chemical and Biological Separations Apply for PD 15 1417 Funding Number: PD 15 1417 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Particulate and Multiphase Processes Apply for PD 15 1415 Funding Number: PD 15 1415 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Combustion and Fire Systems Apply for PD 15 1407 Funding Number: PD 15 1407 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Thermal Transport Processes Apply for PD 15 1406 Funding Number: PD 15 1406 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biophotonics Apply for PD 15 7236 Funding Number: PD 15 7236 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Catalysis and Biocatalysis Apply for PD 15 1401 Funding Number: PD 15 1401 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Environmental Sustainability Apply for PD 15 7643 Funding Number: PD 15 7643 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| FY15 Supplemental for Studies of Friction, Rolling Contact Fatigue and Wear in Rails and Wheels, NRC Apply for FR RRD 15 016 Funding Number: FR RRD 15 016 Agency: DOT/Federal Railroad Administration Category: Science and Technology and other Research and Development Funding Amount: $305,000 |
| Strategic Habitat Conservation for the Least Bells vireo in the Santa Clara River Apply for F15AS00401 Funding Number: F15AS00401 Agency: Fish and Wildlife Service Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Joint Fire Science Program (JFSP) FY 16 Pre funding Notice Potential Topics Apply for L16AS00000 Funding Number: L16AS00000 Agency: Bureau of Land Management Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Research and Resotration through the Santa Clara River Reserve Apply for F15AS00404 Funding Number: F15AS00404 Agency: Fish and Wildlife Service Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 15 BCRP BREAKTHROUGH2 FL3", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
